Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Advances in incretin-based drug discovery in 2025.
Nat. Rev. Endocrinol., DOI: 10.1038/s41574-025-01219-4 (2025)
The efficacy of anti-obesity drugs that use glucagon-like peptide 1
receptor agonism and glucose-dependent insulinotropic polypeptide
agonism raises critical questions about how next-generation drugs might
offer increased metabolic benefits. In 2025, new research into
incretin-based treatments has brought us closer to answering these
questions.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
ISSN (print) / ISBN
1759-5029
e-ISSN
1759-5037
Journal
Nature Reviews - Endocrinology
Publisher
Nature Publishing Group
Publishing Place
New York, NY
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)